EMA Authorised: Cevenfacta (Eptacog beta (activated)) — Laboratoire Francais du Fractionnement et des Biotechnologies

View source ↗

Summary

The EMA authorised Cevenfacta (eptacog beta activated) for treatment of bleeding in Hemophilia A and B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Cevenfacta (eptacog beta activated)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A;Hemophilia B. MAH: Laboratoire Francais du Fractionnement et des Biotechnologies. Decision date: 19/05/2022